Symbol="GTBP"
AssetType="Common Stock"
Name="GT Biopharma Inc"
Description="GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California."
CIK="109657"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1825 K STREET, SUITE 510, WASHINGTON, D.C., DC, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="10526700"
EBITDA="-6760000"
PERatio="None"
PEGRatio="None"
BookValue="0.354"
DividendPerShare="0"
DividendYield="0"
EPS="-0.55"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.512"
ReturnOnEquityTTM="-1.016"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.55"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="3.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.857"
EVToRevenue="-"
EVToEBITDA="-0.751"
Beta="0.955"
num_52WeekHigh="3.1"
num_52WeekLow="0.18"
num_50DayMovingAverage="0.31"
num_200DayMovingAverage="0.965"
SharesOutstanding="37434900"
DividendDate="2017-08-21"
ExDividendDate="None"
symbol="GTBP"
open="0.31"
high="0.31"
low="0.28"
price="0.28"
volume="481462.00"
latest_trading_day="2023-07-07"
previous_close="0.31"
change="-0.03"
change_percent="-9.2903%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="345263"
Change_recent_avg="-0.01"
Delta_recent_avg="0.07"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-2.96"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="1139"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0172.jpeg"
image_negative_thumbnail_id_2="1120"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0153.jpeg"
image_neutral_thumbnail_id_1="574"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_neutral_thumbnail_id_2="545"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0054.jpeg"
image_positive_thumbnail_id_1="669"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0039.jpeg"
image_positive_thumbnail_id_2="990"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0152.jpeg"
image_professor_thumbnail_id_1="1190"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
image_professor_thumbnail_id_2="1191"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
